NTLA - Intellia Therapeutics, Inc.

13.44
0.290   2.158%

Share volume: 3,311,227
Last Updated: 03-06-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$13.15
0.29
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 25%
Dept financing 30%
Liquidity 50%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-12.95%
1 Month
7.61%
3 Months
42.37%
6 Months
13.51%
1 Year
29.86%
2 Year
-55.23%
Key data
Stock price
$13.44
P/E Ratio 
0.00
DAY RANGE
$12.55 - $13.54
EPS 
-$3.81
52 WEEK RANGE
$5.90 - $28.25
52 WEEK CHANGE
$42.07
MARKET CAP 
1.041 B
YIELD 
N/A
SHARES OUTSTANDING 
118.134 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.97
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,835,899
AVERAGE 30 VOLUME 
$4,189,908
Company detail
CEO: John M. Leonard
Region: US
Website: intelliatx.com
Employees: 600
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.

Recent news